ZA202404443B - Compositions and methods for oral administration - Google Patents

Compositions and methods for oral administration

Info

Publication number
ZA202404443B
ZA202404443B ZA2024/04443A ZA202404443A ZA202404443B ZA 202404443 B ZA202404443 B ZA 202404443B ZA 2024/04443 A ZA2024/04443 A ZA 2024/04443A ZA 202404443 A ZA202404443 A ZA 202404443A ZA 202404443 B ZA202404443 B ZA 202404443B
Authority
ZA
South Africa
Prior art keywords
polypeptide
compositions
methods
oral administration
amino acid
Prior art date
Application number
ZA2024/04443A
Other languages
English (en)
Inventor
Ngoc Thai
Jonathan Pollett
Original Assignee
Imagine Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imagine Pharma Llc filed Critical Imagine Pharma Llc
Publication of ZA202404443B publication Critical patent/ZA202404443B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
ZA2024/04443A 2021-12-11 2024-06-07 Compositions and methods for oral administration ZA202404443B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163288579P 2021-12-11 2021-12-11
PCT/US2022/081277 WO2023108126A1 (en) 2021-12-11 2022-12-09 Compositions and methods for oral administration

Publications (1)

Publication Number Publication Date
ZA202404443B true ZA202404443B (en) 2025-10-29

Family

ID=86731317

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2024/04443A ZA202404443B (en) 2021-12-11 2024-06-07 Compositions and methods for oral administration

Country Status (11)

Country Link
US (1) US20250388638A1 (https=)
EP (1) EP4444352A4 (https=)
JP (1) JP2024545981A (https=)
KR (1) KR20240141165A (https=)
CN (1) CN118613284A (https=)
AU (1) AU2022405604A1 (https=)
CA (1) CA3235948A1 (https=)
IL (1) IL312382A (https=)
MX (1) MX2024007105A (https=)
WO (1) WO2023108126A1 (https=)
ZA (1) ZA202404443B (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US20070042392A1 (en) * 2000-02-03 2007-02-22 Nuvelo, Inc. Novel nucleic acids and polypeptides
KR100944034B1 (ko) * 2007-04-19 2010-02-24 한올제약주식회사 프로테아제-내성 폴리펩티드의 경구 투여 제형
KR102497242B1 (ko) * 2016-11-13 2023-02-09 이매진 파마 당뇨병, 고혈압 및 고콜레스테롤혈증을 치료하기 위한 조성물 및 방법
PL3746111T3 (pl) * 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową

Also Published As

Publication number Publication date
WO2023108126A9 (en) 2023-08-24
CA3235948A1 (en) 2023-06-15
MX2024007105A (es) 2024-06-24
EP4444352A4 (en) 2025-12-17
KR20240141165A (ko) 2024-09-25
WO2023108126A1 (en) 2023-06-15
AU2022405604A2 (en) 2024-07-11
IL312382A (en) 2024-06-01
JP2024545981A (ja) 2024-12-17
US20250388638A1 (en) 2025-12-25
AU2022405604A1 (en) 2024-06-13
CN118613284A (zh) 2024-09-06
EP4444352A1 (en) 2024-10-16

Similar Documents

Publication Publication Date Title
MX2024009997A (es) Composicion farmaceutica para inyeccion subcutanea que comprende una variante de hialuronidasa humana ph20 y un farmaco
US11219671B1 (en) Protease inhibitor:protease sensitive expression system, composition and methods for improving the therapeutic activity and specificity of proteins delivered by bacteria
US20230310484A1 (en) Modification of Gene Transcription and Translation Efficiency by 5'UTR Sequence Variation
CN105939723B (zh) 前列腺癌治疗用组合物
IL199263A (en) Glucagon peptide with enhanced solubility, pharmaceutical composition containing it and its uses for drug preparation
JP2021501581A5 (https=)
JP2015502336A5 (https=)
EP2476698A3 (en) Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
NO20084008L (no) HLA-A 3303-begrenset WT1-peptid og farmasoytisk preparat omfattende det samme
CN108307642B (zh) 改造的白介素12及其在制备治疗肿瘤药物中的用途
IL232501A0 (en) Stable analogs of medicinal peptides and polypeptides
MX2020013296A (es) Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas.
AR066648A1 (es) Peptido ciclizado por lactamas, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de canceres artritis reumatica, fibrosis pulmonar e infeccion por vih
JP2017221201A5 (https=)
SI2797950T1 (en) Fusion protein against cancer
CA2809900A1 (en) Use of interleukin-22 in treating viral hepatitis
JP7100639B2 (ja) Ｃｘｃｒ４アンタゴニストおよび使用方法
IL171204A (en) Compounds and pharmaceutical compositions containing them and use thereof for the preparation of medicaments
JP2018521977A5 (https=)
ZA202404443B (en) Compositions and methods for oral administration
Przetak et al. Cloning of cDNA for human granzyme 3
JP2021531002A5 (https=)
PH12022551985A1 (en) Compositions and methods for delivering pharmaceutically active agents
WO2008029138A3 (en) Peptides and methods
WO2024254543A2 (en) Recombinant ancestral variant asparaginases and uses in managing cancer